OctoPlus wins drug manufacturing contract from existing client
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today
that it has received a commitment from an existing client for OctoPlus to
manufacture additional drug product for this client. The contract value will
make a material contribution to OctoPlus' annual revenues in 2012. Further
financial details are not disclosed.
At OctoPlus we provide formulation development and clinical material
manufacturing services to biotech and pharmaceutical companies worldwide. In
addition to our expertise in formulation and manufacturing, we offer our clients
drug delivery technologies for the development of controlled release versions of
existing or new drugs.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and
manufacture of improved injectable pharmaceuticals based on our proprietary drug
delivery technologies that exhibit fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus also focuses on the development of long-acting, controlled release
versions of known protein therapeutics, peptides and small molecules, including
specialty generics.
The clinically most advanced product incorporating our technology is Locteron®,
a controlled release formulation of interferon alpha for the treatment of
chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October
2008. Locteron is being manufactured for Biolex by OctoPlus and has completed
Phase IIb clinical studies with superior clinical data versus current treatment.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more
information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of the Company and the industry in
which it operates. These statements are based on OctoPlus N.V.'s current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF format:
http://hugin.info/137076/R/1565544/485917.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1565544]
Unternehmensinformation / Kurzprofil:
Datum: 22.11.2011 - 07:30 Uhr
Sprache: Deutsch
News-ID 90011
Anzahl Zeichen: 4112
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 168 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus wins drug manufacturing contract from existing client"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
